Last reviewed · How we verify
NCT07077252
Phase I/II Study of SCTB39G in Advanced Solid Tumours
Phase 1, PHASE2 trial testing SCTB39G in Advanced Malignant Solid Tumor in 30 participants. Not yet recruiting.
26 September 2027
Quick facts
| Lead sponsor | Sinocelltech Ltd. |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 28 July 2025 |
| Primary completion | 26 September 2027 |
| Estimated completion | 17 October 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- SCTB39G — full drug profile →
Conditions studied
- Advanced Malignant Solid Tumor — all drugs for Advanced Malignant Solid Tumor →
Sponsor
Sinocelltech Ltd. — full company profile →
Who can join
Adults 18 to 70, any sex, with Advanced Malignant Solid Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB39G as a monotherapy in adult patients with advanced malignant solid tumours. This study is an open label, multicentre, dose-escalation and dose-expansion Phase I/II clinical trial.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07077252
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced Malignant Solid Tumor
Currently open trials in the same condition.
- NCT07293754 — An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07050641 — Phase I/II Study of SCTB39-1 in Advanced Solid Tumours · Phase 1, PHASE2 · recruiting
- NCT06718946 — Study on the Safety and Efficacy of Intravenous Administration of IDOV-SAFETM in the Treatment of Advanced Solid Tumors · EARLY_PHASE1 · recruiting
- NCT06592417 — To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors · Phase 1 · recruiting
- NCT05477849 — A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients with S · Phase 1 · recruiting
Other Sinocelltech Ltd. trials
Trials by the same sponsor.
- NCT07244510 — Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis Suppurativa · Phase 2 · not yet recruiting
- NCT07050641 — Phase I/II Study of SCTB39-1 in Advanced Solid Tumours · Phase 1, PHASE2 · recruiting
- NCT06769984 — A Study of SCTT11 in Healthy Participants and Participants with Thyroid Eye Disease. · Phase 1, PHASE2 · not yet recruiting
- NCT06801509 — A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine · Phase 1, PHASE2 · not yet recruiting
- NCT06754605 — A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Respiratory Syncytial Virus Vaccine · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07077252 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sinocelltech Ltd.
- Last refreshed: 22 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07077252.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing